Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $27.33.
A number of analysts have commented on SBPH shares. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 16th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Spring Bank Pharmaceuticals by 14.8% in the fourth quarter. BlackRock Inc. now owns 32,961 shares of the company’s stock worth $443,000 after acquiring an additional 4,259 shares during the last quarter. Wells Fargo & Company MN acquired a new position in shares of Spring Bank Pharmaceuticals in the fourth quarter worth $101,000. Sectoral Asset Management Inc raised its holdings in shares of Spring Bank Pharmaceuticals by 9.7% in the third quarter. Sectoral Asset Management Inc now owns 123,383 shares of the company’s stock worth $2,078,000 after acquiring an additional 10,883 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Spring Bank Pharmaceuticals in the fourth quarter worth $172,000. Finally, AXA raised its holdings in shares of Spring Bank Pharmaceuticals by 7.6% in the fourth quarter. AXA now owns 266,585 shares of the company’s stock worth $3,583,000 after acquiring an additional 18,859 shares during the last quarter. 28.65% of the stock is owned by institutional investors.
Spring Bank Pharmaceuticals (SBPH) traded down $0.27 on Friday, reaching $15.18. The company’s stock had a trading volume of 24,374 shares, compared to its average volume of 27,574. Spring Bank Pharmaceuticals has a one year low of $7.95 and a one year high of $18.93.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/spring-bank-pharmaceuticals-inc-sbph-receives-27-33-average-pt-from-analysts.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.